Outcomes of the 93 HCV-MC patients according to the type of treatment
| Parameter . | All MC patients (n = 93) . | Peg-IFN-α/ribavirin (n = 55) . | RTX-Peg-IFN-α/ribavirin (n = 38) . | P . |
|---|---|---|---|---|
| Delay to clinical response, mo | 6.8 ± 4.7 | 8.4 ± 4.7 | 5.4 ± 4.0 | .004 |
| Clinical response | ||||
| CR | 68 (73.1) | 40 (72.7) | 28 (73.7) | .98 |
| PR | 22 (23.6) | 13 (23.6) | 9 (23.7) | |
| NR | 3 (3.2) | 2 (3.6) | 1 (2.6) | |
| Relapse | 17 (18.8) | 10 (18.8) | 7 (18.9) | |
| Immunologic response | ||||
| CR | 49 (52.7) | 24 (43.6) | 26 (68.4) | .001 |
| PR | 35 (37.6) | 25 (45.4) | 10 (26.3) | |
| NR | 8 (8.6) | 6 (10.9) | 2 (5.2) | |
| Relapse | 17 (18.3) | 10 (18.1) | 7 (18.4) | |
| Virologic response | ||||
| SVR | 55 (59.1) | 33 (60) | 22 (57.9) | > .999 |
| NR | 38 (40.8) | 22 (40) | 16 (42.1) | |
| Death | 5 (5.4) | 2 (3.6) | 3 (7.9) | .70 |
| Cirrhosis | 1 (1.1) | — | 1 (2.6) | |
| Liver carcinoma | 3 (3.2) | 2 (3.6) | 1 (2.6) | |
| Unknown | 1 (1.1) | — | 1 (2.6) |
| Parameter . | All MC patients (n = 93) . | Peg-IFN-α/ribavirin (n = 55) . | RTX-Peg-IFN-α/ribavirin (n = 38) . | P . |
|---|---|---|---|---|
| Delay to clinical response, mo | 6.8 ± 4.7 | 8.4 ± 4.7 | 5.4 ± 4.0 | .004 |
| Clinical response | ||||
| CR | 68 (73.1) | 40 (72.7) | 28 (73.7) | .98 |
| PR | 22 (23.6) | 13 (23.6) | 9 (23.7) | |
| NR | 3 (3.2) | 2 (3.6) | 1 (2.6) | |
| Relapse | 17 (18.8) | 10 (18.8) | 7 (18.9) | |
| Immunologic response | ||||
| CR | 49 (52.7) | 24 (43.6) | 26 (68.4) | .001 |
| PR | 35 (37.6) | 25 (45.4) | 10 (26.3) | |
| NR | 8 (8.6) | 6 (10.9) | 2 (5.2) | |
| Relapse | 17 (18.3) | 10 (18.1) | 7 (18.4) | |
| Virologic response | ||||
| SVR | 55 (59.1) | 33 (60) | 22 (57.9) | > .999 |
| NR | 38 (40.8) | 22 (40) | 16 (42.1) | |
| Death | 5 (5.4) | 2 (3.6) | 3 (7.9) | .70 |
| Cirrhosis | 1 (1.1) | — | 1 (2.6) | |
| Liver carcinoma | 3 (3.2) | 2 (3.6) | 1 (2.6) | |
| Unknown | 1 (1.1) | — | 1 (2.6) |
Except where indicated otherwise, values are mean ± SD and n (%). The time point to evaluate the response to therapy was at the end of 12 months of antiviral therapy. Relapses and sustained virologic responses were evaluated 6 months later (ie, 18 months after starting antiviral therapy). Time to clinical response was tested with the Wilcoxon test. Categorical variables were compared using the Fisher exact or χ2 tests, and continuous variables using the t test.
CR indicates complete remission; PR, partial response; NR, nonresponder; SVR, sustained virologic response; and —, not applicable.